Drug delivery for the treatment of endometriosis and uterine fibroids

David R Friend
Drug delivery and translational research · 2017 · vol. 7(6) , pp. 829–839 · doi:10.1007/s13346-017-0423-2 · PMID:28828592 · W2745998266
review OA: closed CC0 ⤵ 14 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

Existing drug delivery systems like contraceptives and GnRH products, along with novel nanotechnology-based approaches, are used to manage endometriosis and uterine fibroids.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This paper reviews how drug delivery strategies have been used to manage endometriosis and uterine fibroids, contrasting existing delivery systems repurposed for symptom relief (such as vaginal rings, transdermal patches, intrauterine systems, implants, and long-acting GnRH products) with newer nanotechnology-based approaches designed to target underlying mechanisms like oxidative stress, angiogenesis, and matrix degradation. It describes representative long-acting hormonal and local delivery platforms, and lists nanoparticle materials (including silica, PLGA, cerium oxide, dendrimers, and chitosan/polyethyleneamine) investigated particularly for endometriosis and to a lesser extent for fibroids. A key limitation is that, as a narrative review, it does not provide new experimental results or a unified quantitative effectiveness comparison across the many cited modalities. This paper is centrally about endometriosis—reviewing drug delivery systems and nanotechnology approaches for endometriosis and uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Drug Delivery Systems Endometriosis Leiomyoma Aromatase Inhibitors Aromatase Inhibitors Aromatase Inhibitors Drug Delivery Systems Drug Repositioning Endometriosis Estrogen Antagonists Estrogen Antagonists Estrogen Antagonists Female Humans Leiomyoma Nanotechnology

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (14)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:19.560968+00:00
License: CC0 · commercial use OK